Oculis to Participate in Upcoming June Investor Conferences

Rhea-AI Summary

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in two major investor conferences in June 2025. CEO Riad Sherif will present a fireside chat at the Goldman Sachs Annual Healthcare Conference in Miami on June 10th from 9:20 to 9:55am ET. Additionally, Dr. Sherif will attend the J.P. Morgan European Healthcare Conference in London on June 12th. The company will be available for one-on-one meetings during both conferences, with interested investors advised to contact conference representatives for meeting arrangements. Webcast links will be made available on Oculis's website under the Investors & Media section.

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:

Goldman Sachs Annual Healthcare Conference
June 9-11; Miami, FL, U.S.
Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET.

J.P. Morgan European Healthcare Conference  
June 12; London, U.K.
Riad Sherif, MD, Chief Executive Officer, will be attending.

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

FAQ

When is Oculis (OCS) presenting at the Goldman Sachs Healthcare Conference 2025?

Oculis CEO Riad Sherif will present a fireside chat on June 10th, 2025, from 9:20 to 9:55am ET at the Goldman Sachs Annual Healthcare Conference in Miami.

Which investor conferences is Oculis (OCS) attending in June 2025?

Oculis is attending two conferences: the Goldman Sachs Annual Healthcare Conference in Miami (June 9-11) and the J.P. Morgan European Healthcare Conference in London (June 12).

How can investors meet with Oculis management at the June 2025 conferences?

Investors interested in one-on-one meetings should contact their representatives at the sponsoring institutions (Goldman Sachs or J.P. Morgan) to request meetings.

Where can investors find the webcast links for Oculis's June 2025 conference presentations?

Webcast links will be posted on the Oculis website's Events & Presentation page under the Investors & Media section when available.